Clinical Trial Update: First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours [Phase 1]

View source ↗

Summary

This clinical trial update reports the completion of a first-in-human Phase 1 study evaluating AZD8701 with or without durvalumab in adults with advanced solid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Clear Cell Renal Cell Carcinoma
• Gastroesophageal Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Small Cell Lung Cancer
• Squamous Cell Carcinoma of the Head and Neck
• Triple-negative Breast Cancer

Drugs mentioned

• AZD8701
• IMFINZI (DURVALUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer | Phase 1 | Status: COMPLETED